InflaRx N.V.
IFRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. With a market capitalization of $319.8M, it sits in small-cap territory. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Market Cap
$319.8M
Beta
2.54
P/E (TTM)
—
P/E (Fwd)
-5.39
EPS (TTM)
$-0.58
EPS (Fwd)
$-0.40
ROE
-38.5%
ROA
-18.5%
Cash
$158.5M
Total Debt
$833,179
Free CF
-$4.3M
52W Change
40.5%
Annual Financials
Cash vs Debt
Where IFRX stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, IFRX finished 52.20% above its 150-day moving average ($1.59) and 63.51% above its 200-day moving average ($1.48). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IFRX overbought or oversold?
At the August 27, 2026 close, IFRX's RSI(14) was 79.2, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $158.5M in cash comfortably exceeding the $833K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$4.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -38.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, IFRX tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, IFRX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence InflaRx N.V.'s trajectory.